INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/31/24
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/30/24
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/19/24
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/17/24
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024InvestorPlace • 05/17/24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/16/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/15/24
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/24
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities lawsPRNewsWire • 04/19/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/19/24
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/12/24
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/04/24
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setbackMarket Watch • 04/02/24
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side EffectsInvestors Business Daily • 04/02/24
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levelsReuters • 04/02/24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/27/24